Skip to main content
. 2021 Jun 25;14(5):1689–1704. doi: 10.1111/cts.13061

FIGURE 1.

FIGURE 1

Overview of criteria/conditions when an RI study may or may not be recommended. CL, clearance; FDA, US Food and Drug Administration; EMA, European Medicines Agency; PK, pharmacokinetic; RI, renal impairment